Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Sagimet Confirms Phase 3 Denifanstat Success In Moderate To Severe Acne With EADV 2025 Oral Presentation In Paris Scheduled

Author: Benzinga Newsdesk | September 17, 2025 07:16am

Denifanstat met all primary and secondary endpoints versus placebo

Denifanstat was generally well tolerated

Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, for development in acne

Posted In: SGMT